Cyclerion Therapeutics (CYCN) Competitors $2.95 +0.06 (+2.08%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYCN vs. CEMI, CELU, DARE, LEXX, DYAI, ENLV, ACST, ESLA, SRZN, and LIANShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Chembio Diagnostics (CEMI), Celularity (CELU), Daré Bioscience (DARE), Lexaria Bioscience (LEXX), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Acasti Pharma (ACST), Estrella Immunopharma (ESLA), Surrozen (SRZN), and LianBio (LIAN). These companies are all part of the "medical" sector. Cyclerion Therapeutics vs. Chembio Diagnostics Celularity Daré Bioscience Lexaria Bioscience Dyadic International Enlivex Therapeutics Acasti Pharma Estrella Immunopharma Surrozen LianBio Cyclerion Therapeutics (NASDAQ:CYCN) and Chembio Diagnostics (NASDAQ:CEMI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends. Which has more risk & volatility, CYCN or CEMI? Cyclerion Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Is CYCN or CEMI more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to Chembio Diagnostics' net margin of -47.03%. Cyclerion Therapeutics' return on equity of -66.84% beat Chembio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -66.84% -57.28% Chembio Diagnostics -47.03%-113.57%-38.22% Which has higher earnings and valuation, CYCN or CEMI? Cyclerion Therapeutics has higher earnings, but lower revenue than Chembio Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$1.62M4.93-$5.26MN/AN/AChembio Diagnostics$48.34M0.35-$23.29M-$1.20-0.38 Do analysts prefer CYCN or CEMI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AChembio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media prefer CYCN or CEMI? In the previous week, Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Chembio Diagnostics'average media sentiment score. Company Overall Sentiment Cyclerion Therapeutics Neutral Chembio Diagnostics Neutral Do institutionals & insiders have more ownership in CYCN or CEMI? 75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Chembio Diagnostics shares are held by institutional investors. 36.1% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 3.3% of Chembio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in CYCN or CEMI? Chembio Diagnostics received 239 more outperform votes than Cyclerion Therapeutics when rated by MarketBeat users. However, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 51.22% of users gave Chembio Diagnostics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Chembio DiagnosticsOutperform Votes27351.22% Underperform Votes26048.78% SummaryCyclerion Therapeutics beats Chembio Diagnostics on 8 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.00M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / Sales4.93381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.645.324.665.02Net Income-$5.26M$153.56M$119.06M$225.46M7 Day Performance-2.64%0.11%0.80%0.37%1 Month Performance11.74%15.22%5.65%3.57%1 Year Performance19.43%41.14%36.76%29.44% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics0.8922 of 5 stars$2.95+2.1%N/A+13.3%$8.00M$1.62M0.0030Short Interest ↑Gap UpHigh Trading VolumeCEMIChembio DiagnosticsN/A$0.46flatN/A+0.0%$16.71M$48.34M-0.38337Analyst ForecastCELUCelularity0.068 of 5 stars$1.71-8.1%N/A-33.1%$33.12M$33.52M0.00220Gap UpDAREDaré Bioscience1.5998 of 5 stars$3.91+7.1%$24.00+513.8%-15.4%$32.93M$2.84M-3.4930LEXXLexaria Bioscience2.705 of 5 stars$2.52-4.9%$11.00+336.5%+60.0%$32.47M$411,019.00-5.737Short Interest ↓DYAIDyadic International2.2998 of 5 stars$1.09+2.8%$6.00+451.0%-33.3%$31.84M$1.80M-3.897Positive NewsGap UpENLVEnlivex Therapeutics3.3974 of 5 stars$1.48+0.7%$6.00+305.4%+2.4%$31.69MN/A-1.2570News CoverageACSTAcasti Pharma2.6154 of 5 stars$3.37-0.9%$10.00+196.7%+39.8%$31.68MN/A-2.9632ESLAEstrella Immunopharma1.3098 of 5 stars$0.86-4.4%N/A-52.5%$31.12MN/A-0.44N/APositive NewsGap DownSRZNSurrozen2.0512 of 5 stars$9.70-2.9%N/A+113.9%$31.03M$12.50M0.0042Gap UpLIANLianBio1.2118 of 5 stars$0.28flat$3.50+1,149.1%-92.9%$30.28MN/A-0.35110Gap Up Related Companies and Tools Related Companies CEMI Competitors CELU Competitors DARE Competitors LEXX Competitors DYAI Competitors ENLV Competitors ACST Competitors ESLA Competitors SRZN Competitors LIAN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
